Business
Director Appointment
Director Appointment.
About this update from Persimmon Plc
[{"type":"text","content":"\n \nRNS Number : 4051W Persimmon PLC 17 April 2019 \n\n17 April 2019\n \nPersimmon plc\n \nAppointment of Claire Thomas as Independent Non-Executive Director\n \nPersimmon Plc is pleased to announce that Claire Thomas will join the Board as an Independent Non-Executive Director with effect from 1 August 2019. Claire will also be appointed as a member of the Company's Remuneration and Nomination Committees on the same date. \n \nClaire Thomas has been Senior Vice President, HR at GlaxoSmithKline PLC for more than 10 years with responsibility for the global HR function. Claire has over 28 years' experience of operating in a complex, global HR environment and has a wide range of experience including advising boards of directors, supporting remuneration and nomination committees, succession planning, strategic planning and corporate restructuring. Claire was also a Non-Executive Director for the UK Government's Department of Energy and Climate Change.\n \nRoger Devlin, Chairman of Persimmon, said: \"We are building a new Persimmon with progressive changes being made to our customer care, governance and remuneration. As part of that plan, we are further strengthening our board and remuneration committee with the appointment of a new, forward-thinking independent director with a strong track record in a highly respected global organisation. I am pleased to welcome Claire to Persimmon's board.\" \nNo further information is required to be disclosed pursuant to Listing Rule 9.6.13.\n \nFor further information, please contact:\n \n\n\n\nSimon Rigby\n\n\n\n\nKevin Smith\n\n\n\n\nJos Bieneman\n\n\n\n\nCitigate Dewe Rogerson\n\n\n\n\nTel: +44 (0) 20 7638 9571\n\n\n\n \n \n\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com. END BOASFUFMMFUSEFL\n ","length":3797,"tagName":"div"}]